Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

NCT07408804 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma (HCC)

Interventions

PROCEDURE: TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib)
DRUG: Lenvatinib

Sponsor

Bangladesh Medical University